Characterization and management of on-target, off-tumor toxicities related to talquetamab. (A) Incidence and severity of weight loss, dermatologic AEs, and oral AEs. (B) Partial or full recovery rates of weight loss, dermatologic AEs, and oral AEs. (C) Detailed management strategies for weight loss, dermatologic AEs, and oral AEs. (D) Talquetamab regimen adjustments, including treatment interruption (dose holds/delays), modification (reductions in dosing frequency/intensity), or discontinuation.